WO2001041750A3 - Nouvelles combinaisons therapeutiques de (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one et neuroleptiques destines au traitement ou a la prevention de troubles psychotiques - Google Patents

Nouvelles combinaisons therapeutiques de (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one et neuroleptiques destines au traitement ou a la prevention de troubles psychotiques Download PDF

Info

Publication number
WO2001041750A3
WO2001041750A3 PCT/US2000/033060 US0033060W WO0141750A3 WO 2001041750 A3 WO2001041750 A3 WO 2001041750A3 US 0033060 W US0033060 W US 0033060W WO 0141750 A3 WO0141750 A3 WO 0141750A3
Authority
WO
WIPO (PCT)
Prior art keywords
combinations
dioxino
neuroleptics
benzylamino
indol
Prior art date
Application number
PCT/US2000/033060
Other languages
English (en)
Other versions
WO2001041750A2 (fr
Inventor
Karen Lovell Marquis
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MXPA02005649A priority Critical patent/MXPA02005649A/es
Priority to IL14966900A priority patent/IL149669A0/xx
Application filed by American Home Prod filed Critical American Home Prod
Priority to AU19490/01A priority patent/AU784211B2/en
Priority to KR1020027007286A priority patent/KR100772854B1/ko
Priority to HU0203309A priority patent/HUP0203309A3/hu
Priority to EP00982461A priority patent/EP1235570A2/fr
Priority to CA002396351A priority patent/CA2396351C/fr
Priority to BR0016168-3A priority patent/BR0016168A/pt
Priority to EA200200656A priority patent/EA005002B1/ru
Priority to JP2001543095A priority patent/JP5557409B2/ja
Priority to NZ519381A priority patent/NZ519381A/en
Publication of WO2001041750A2 publication Critical patent/WO2001041750A2/fr
Publication of WO2001041750A3 publication Critical patent/WO2001041750A3/fr
Priority to IL149669A priority patent/IL149669A/en
Priority to NO20022739A priority patent/NO20022739D0/no
Priority to HK02107378.5A priority patent/HK1045942A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des combinaisons thérapeutiques, utiles dans le traitement ou la prévention de troubles psychotiques; elle concerne également des compositions pharmaceutiques contenant ces combinaisons, ainsi que l'utilisation de celles-ci dans le traitement ou la prophylaxie de troubles psychotiques.
PCT/US2000/033060 1999-12-10 2000-12-07 Nouvelles combinaisons therapeutiques de (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one et neuroleptiques destines au traitement ou a la prevention de troubles psychotiques WO2001041750A2 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
EA200200656A EA005002B1 (ru) 1999-12-10 2000-12-07 НОВЫЕ ТЕРАПЕВТИЧЕСКИЕ КОМБИНАЦИИ (S)-2-(БЕНЗИЛАМИНОМЕТИЛ)-2,3,8,9-ТЕТРАГИДРО-7H-1,4-ДИОКСИН [2,3-e]ИНДОЛ-8-ОНА И НЕЙРОЛЕПТИКОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСИХОТИЧЕСКИХ РАССТРОЙСТВ
BR0016168-3A BR0016168A (pt) 1999-12-10 2000-12-07 Combinações terapêuticas de (s)-2-(benzilaminometil)-2,3,8,9tetrahidro-7h-1,4-dioxi no[2,3 -e]indol-8-ona e neurolépticos para o tratamento ou prevenção de distúrbios psicóticos
AU19490/01A AU784211B2 (en) 1999-12-10 2000-12-07 Combinations of (S)-2(benzylamino-methyl)-2,3,8,9,- tetrahydro-7H-1,4-dioxino(2,3)-E indol-8-one and neuroleptics
IL14966900A IL149669A0 (en) 1999-12-10 2000-12-07 NEW THERAPEUTIC COMBINATIONS OF (S) -2-(BENZYLAMINO-METHYL)-2,3,8,9-TETRAHYDRO-7H-1,4-DIOXINO[2,3-e] INDOL-8-ONE AND NEUROLEPTICS FOR THE TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS
HU0203309A HUP0203309A3 (en) 1999-12-10 2000-12-07 Therapeutic combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics for treatment or prevention of phychotic disorders and pharmaceutical compositions containing them
EP00982461A EP1235570A2 (fr) 1999-12-10 2000-12-07 Nouvelles combinaisons therapeutiques de (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino 2,3-e]indol-8-one et neuroleptiques destines au traitement ou a la prevention de troubles psychotiques
JP2001543095A JP5557409B2 (ja) 1999-12-10 2000-12-07 （ｓ）−２−（ベンジルアミノメチル）−２，３，８，９−テトラヒドロ−７ｈ−１，４−ジオキシノ（２，３）ｅインドール−８−オンと神経遮断薬との組合せ
MXPA02005649A MXPA02005649A (es) 1999-12-10 2000-12-07 Nuevas combinaciones terapeuticas de (s)-2 -(bencilamino -metil)-2, 3, 8, 9-tetrahidro-7h -1, 4-dioxino(2-3 -e]indol-8 -ona y agentes neurolepticos para el tratamiento o prevencion de trastornos psicoticos.
KR1020027007286A KR100772854B1 (ko) 1999-12-10 2000-12-07 (Ｓ)-2-(벤질아미노-메틸)-2,3,8,9-테트라하이드로-7Ｈ-1,4-디옥시노[2,3-ｅ]인돌-8-온 및 항정신병 제제의 배합물
CA002396351A CA2396351C (fr) 1999-12-10 2000-12-07 Nouvelles combinaisons therapeutiques de (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one et neuroleptiques destines au traitement ou a la prevention de troubles psychotiques
NZ519381A NZ519381A (en) 1999-12-10 2000-12-07 New therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders
IL149669A IL149669A (en) 1999-12-10 2002-05-15 Combinations of (S) - 2) Benzylamino – methyl) 2,9,8,3,2 –– Tetrahydro-H7–1, 4 – Dioxino] E – 3,2 [Indole-8 – on and neuroleptic for the treatment or prevention of Psychotic arrangements
NO20022739A NO20022739D0 (no) 1999-12-10 2002-06-07 Nye terapeutiske kombinasjoner av (S)-2-(benzylamino-metyl)- 2,3,8,9-tetrahydro-7H-1,4-dioksino[2,3-e]indol-8-on ognevroleptika for behandling eller forhindring av psykotiskelidelser
HK02107378.5A HK1045942A1 (zh) 1999-12-10 2002-10-09 結合(s)-2-(苄胺甲基)-2，3，8，9，-四氫-7h-1，4-二氧(2，3)吲-8-酮及精神抑制藥

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45860799A 1999-12-10 1999-12-10
US09/458,607 1999-12-10

Publications (2)

Publication Number Publication Date
WO2001041750A2 WO2001041750A2 (fr) 2001-06-14
WO2001041750A3 true WO2001041750A3 (fr) 2002-02-14

Family

ID=23821437

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/033060 WO2001041750A2 (fr) 1999-12-10 2000-12-07 Nouvelles combinaisons therapeutiques de (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one et neuroleptiques destines au traitement ou a la prevention de troubles psychotiques

Country Status (20)

Country Link
EP (1) EP1235570A2 (fr)
JP (1) JP5557409B2 (fr)
KR (1) KR100772854B1 (fr)
CN (1) CN1230164C (fr)
AR (1) AR026756A1 (fr)
AU (1) AU784211B2 (fr)
BR (1) BR0016168A (fr)
CA (1) CA2396351C (fr)
CZ (1) CZ20021880A3 (fr)
EA (1) EA005002B1 (fr)
HK (1) HK1045942A1 (fr)
HU (1) HUP0203309A3 (fr)
IL (2) IL149669A0 (fr)
MX (1) MXPA02005649A (fr)
NO (1) NO20022739D0 (fr)
NZ (1) NZ519381A (fr)
PL (1) PL355292A1 (fr)
TW (1) TWI222864B (fr)
WO (1) WO2001041750A2 (fr)
ZA (1) ZA200205484B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG147450A1 (en) 2003-10-29 2008-11-28 Wyeth Corp Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
CA2597616A1 (fr) 2005-02-17 2006-08-24 Wyeth Derive d'indole, benzothiophene, benzofurane et indene a fusion cycloalkyle
SG188144A1 (en) * 2008-02-13 2013-03-28 Targacept Inc Alpha 7 nicotinic agonists and antipsychotics

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0771800A2 (fr) * 1995-11-06 1997-05-07 American Home Products Corporation Dérivés dioxino et leur utilisation comme agonistes de la dopamine
WO1998029415A1 (fr) * 1996-12-27 1998-07-09 Knoll Aktiengesellschaft Derives de heteroarylsulfamide et compositions pharmaceutiques les contenant

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2987484B2 (ja) * 1995-03-16 1999-12-06 大塚製薬 株式会社 カルボスチリル誘導体の製造方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0771800A2 (fr) * 1995-11-06 1997-05-07 American Home Products Corporation Dérivés dioxino et leur utilisation comme agonistes de la dopamine
US5962465A (en) * 1995-11-06 1999-10-05 American Home Products Corporation Aminomethyl-2,3,8,9-tetrahydro-7H-1,4-dioxino- 2,3-e!-indol-8-ones and derivatives
WO1998029415A1 (fr) * 1996-12-27 1998-07-09 Knoll Aktiengesellschaft Derives de heteroarylsulfamide et compositions pharmaceutiques les contenant

Also Published As

Publication number Publication date
TWI222864B (en) 2004-11-01
BR0016168A (pt) 2002-08-20
AR026756A1 (es) 2003-02-26
HUP0203309A2 (hu) 2003-01-28
CA2396351C (fr) 2009-11-10
CA2396351A1 (fr) 2001-06-14
NZ519381A (en) 2004-04-30
CZ20021880A3 (cs) 2002-08-14
AU1949001A (en) 2001-06-18
EA200200656A1 (ru) 2002-12-26
EA005002B1 (ru) 2004-10-28
CN1230164C (zh) 2005-12-07
CN1409633A (zh) 2003-04-09
JP5557409B2 (ja) 2014-07-23
KR20030016207A (ko) 2003-02-26
AU784211B2 (en) 2006-02-23
PL355292A1 (en) 2004-04-05
ZA200205484B (en) 2003-12-31
NO20022739L (no) 2002-06-07
HK1045942A1 (zh) 2002-12-20
KR100772854B1 (ko) 2007-11-02
MXPA02005649A (es) 2004-09-10
WO2001041750A2 (fr) 2001-06-14
JP2003516350A (ja) 2003-05-13
HUP0203309A3 (en) 2004-12-28
NO20022739D0 (no) 2002-06-07
IL149669A0 (en) 2002-11-10
EP1235570A2 (fr) 2002-09-04
IL149669A (en) 2006-06-11

Similar Documents

Publication Publication Date Title
WO2001041762A3 (fr) Compositions de valdecoxib
EP1259240B8 (fr) Agents de traitement des troubles cutanés, tel le nicotinamide et le cADPR
HUP0104795A3 (en) Azabicycloalkanes as ccr5 modulators, pharmaceutical compositions comprising thereof and their use
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
AU2002361811A1 (en) 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
AU2001266152A1 (en) Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them
CA2402652A1 (fr) Produits viscoelastiques destines a la chirurgie de l'oreille moyenne
AU2001283285A1 (en) Antimicrobial composition and methods of use in the treatment of disease
AU2300001A (en) Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
AU2002247876A1 (en) Herbal composition for treatment of neuronal injuries and neuronal degeneration, methods to prepare the same and uses thereof
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
AU2002363411A1 (en) Novel benzoyl peroxide compositions for the treatment of dermatological disorders and methods for their use
AU1546101A (en) Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
AU4789099A (en) Therapeutic composition based on flavonoids for use in the treatment of tumours with cytotoxic agents
WO2000061231A3 (fr) Utilisation medicale
WO2001041750A3 (fr) Nouvelles combinaisons therapeutiques de (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one et neuroleptiques destines au traitement ou a la prevention de troubles psychotiques
AU2002226060A1 (en) Compositions containing gangliosides for use in the treatment of skin disorders
WO1999051617A3 (fr) 5,6-DICHLORO-2-(ISOPROPYLAMINO)-1-(β-L-RIBOFURANOSYL)-1H-BENZIMIDAZOLE FORME VI
AU2001296173A1 (en) 3,8-diazabicyclo(3.2.1)octanes and their use in the treatment of cardiac arrhythmias
BG104914A (en) Paroxetine maleate
WO2004006887A3 (fr) Compositions et methodes pour le traitement de troubles cutanes
JO2199B1 (en) Replaced pyrrols
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
AU2092300A (en) Use of estrogens and delta-gonadien-21-ol-3,20-diones in the treatment or prophylaxis of cerebral degenerative disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 149669

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2001 543095

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2396351

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000982461

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PV2002-1880

Country of ref document: CZ

Ref document number: 19490/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 519381

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1020027007286

Country of ref document: KR

Ref document number: PA/a/2002/005649

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 008169527

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 200200656

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: PV2002-1880

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2000982461

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020027007286

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 519381

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 519381

Country of ref document: NZ